Attached files

file filename
10-Q - FORM 10-Q - GALECTIN THERAPEUTICS INCd10q.htm
EX-10.2 - COMMON STOCK PURCHASE WARRANT DATED AUGUST 3, 2010 ISSUED TO PETER TRABER - GALECTIN THERAPEUTICS INCdex102.htm
EX-10.1 - CONSULTING AGREEMENT DATED EFFECTIVE JUNE 15, 2010 - GALECTIN THERAPEUTICS INCdex101.htm
EX-31.1 - CERTIFICATION OF CEO & PRESIDENT PURSUANT TO SECTION 302 - GALECTIN THERAPEUTICS INCdex311.htm
EX-32.2 - CERTIFICATION OF CFO TO PURSUANT TO SECTION 906 - GALECTIN THERAPEUTICS INCdex322.htm
EX-10.3 - LETTER AGREEMENT BETWEEN 10X FUND, L.P. AND PRO-PHARMACEUTICALS, INC. - GALECTIN THERAPEUTICS INCdex103.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO SECTION 302 - GALECTIN THERAPEUTICS INCdex312.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Pro-Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Theodore D. Zucconi, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: August 13, 2010      

/s/ Theodore D. Zucconi

    Name:   Theodore D. Zucconi, Ph.D.
    Title:   Chief Executive Officer and President
      (principal executive officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pro-Pharmaceuticals, Inc. and will be retained by Pro-Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.